Rock Springs Capital Management LP Acquires Shares of 96,000 Viking Therapeutics, Inc. $VKTX

Posted by Brian Himes on Jul 28th, 2026

Rock Springs Capital Management LP acquired a new position in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 96,000 shares of the biotechnology company’s stock, valued at approximately $3,124,000.

Other large investors have also recently added to or reduced their stakes in the company. Eversept Partners LP bought a new stake in shares of Viking Therapeutics in the first quarter valued at about $7,781,000. The Manufacturers Life Insurance Company increased its position in Viking Therapeutics by 12.0% during the first quarter. The Manufacturers Life Insurance Company now owns 27,196 shares of the biotechnology company’s stock worth $885,000 after acquiring an additional 2,924 shares during the period. Quantinno Capital Management LP increased its position in Viking Therapeutics by 19.4% during the first quarter. Quantinno Capital Management LP now owns 41,082 shares of the biotechnology company’s stock worth $1,337,000 after acquiring an additional 6,688 shares during the period. Granahan Investment Management LLC increased its position in Viking Therapeutics by 41.0% during the first quarter. Granahan Investment Management LLC now owns 332,192 shares of the biotechnology company’s stock worth $10,810,000 after acquiring an additional 96,606 shares during the period. Finally, Compound Planning Inc. acquired a new stake in Viking Therapeutics in the 1st quarter worth about $277,000. Institutional investors own 76.03% of the company’s stock.

Analyst Ratings Changes

A number of research firms have issued reports on VKTX. BTIG Research reissued a “buy” rating and issued a $125.00 price objective on shares of Viking Therapeutics in a report on Friday, May 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Viking Therapeutics in a report on Friday, July 17th. Truist Financial assumed coverage on shares of Viking Therapeutics in a research report on Wednesday, May 27th. They issued a “buy” rating and a $83.00 price target for the company. Cantor Fitzgerald dropped their price target on shares of Viking Therapeutics from $105.00 to $100.00 and set an “overweight” rating for the company in a research report on Thursday, April 30th. Finally, Morgan Stanley set a $95.00 price target on Viking Therapeutics in a research note on Thursday, April 30th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Viking Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $97.00.

Get Our Latest Stock Analysis on VKTX

Viking Therapeutics Stock Performance

Shares of NASDAQ VKTX opened at $34.87 on Tuesday. The stock has a market capitalization of $4.05 billion, a P/E ratio of -8.42 and a beta of 0.66. The stock’s fifty day moving average is $33.91 and its 200 day moving average is $32.94. Viking Therapeutics, Inc. has a 52 week low of $22.96 and a 52 week high of $43.15.

Viking Therapeutics (NASDAQ:VKTX – Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The biotechnology company reported ($1.37) earnings per share for the quarter, missing the consensus estimate of ($1.01) by ($0.36). During the same period last year, the company earned ($0.41) EPS. Equities research analysts forecast that Viking Therapeutics, Inc. will post -4.7 earnings per share for the current year.

Viking Therapeutics Company Profile

(Free Report)

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Headquartered in San Diego, California, the company’s pipeline leverages small-molecule approaches to target hormone signaling pathways implicated in conditions such as non‐alcoholic steatohepatitis (NASH), dyslipidemia, type 2 diabetes and muscle wasting disorders.

The company’s lead programs include VK2809, a thyroid hormone receptor‐beta agonist designed to reduce liver fat and improve lipid profiles in patients with NASH and dyslipidemia, and VK5211, a selective androgen receptor modulator (SARM) aimed at enhancing muscle mass and function in individuals with muscle wasting conditions.